Literature DB >> 2219727

Processing, assembly, and immunogenicity of human immunodeficiency virus core antigens expressed by recombinant vaccinia virus.

S L Hu1, B M Travis, J Garrigues, J M Zarling, P Sridhar, T Dykers, J W Eichberg, C Alpers.   

Abstract

Recombinant vaccinia viruses that contained regions of the gag-pol open reading frames of human immunodeficiency virus type 1 (HIV-1) were constructed. Cells infected with recombinants containing both gag and protease genes expressed and processed HIV gag antigens efficiently. Processing was much reduced in cells infected with recombinants containing only gag, but not the protease gene. However, significant amounts of p41 were produced by protease-defective recombinants. This protein was immunoreactive with p24-specific monoclonal antibodies and was produced in a truncated form by a recombinant containing a 3' deletion in the p15 coding region of gag ORF. These results indicate that p41 could represent an alternative gag precursor with N-terminal sequences derived from p24 and C-terminal from p15. Ultrastructural analysis of recombinant-infected cells revealed that the gag antigens expressed were assembled into retrovirus-like particles and were secreted into culture medium. This assembly process was not dependent on HIV protease function, because immature core particles were produced by recombinants lacking HIV-1 protease functions. Immunization of mice and chimpanzees with vaccinia-HIVgag recombinant viruses generated both antibody and cell-mediated immune responses to HIV gag antigens. These recombinants are therefore useful not only for studying HIV virion processing and assembly, but also for designing immunogens for the prophylaxis and immunotherapy against AIDS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2219727     DOI: 10.1016/0042-6822(90)90300-g

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  A molecular determinant of human immunodeficiency virus particle assembly located in matrix antigen p17.

Authors:  Y Morikawa; T Kishi; W H Zhang; M V Nermut; D J Hockley; I M Jones
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

3.  Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor.

Authors:  X Yuan; X Yu; T H Lee; M Essex
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

4.  Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production.

Authors:  E O Freed; J M Orenstein; A J Buckler-White; M A Martin
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

5.  Evaluation of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses utilizing B-lymphoblastoid cell lines transduced with the CD4 gene and infected with HIV-1.

Authors:  M J McElrath; M Rabin; M Hoffman; S Klucking; J V Garcia; P D Greenberg
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

6.  Characterization of human immunodeficiency virus type 1 Pr55gag membrane association in a cell-free system: requirement for a C-terminal domain.

Authors:  E J Platt; O K Haffar
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

7.  Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag.

Authors:  D C Porter; L R Melsen; R W Compans; C D Morrow
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

Review 9.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

10.  Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins.

Authors:  M E Hagensee; N Yaegashi; D A Galloway
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.